The dramatic improvement of the survival of clonal HES patients is largely attributable to imatinib which is highly effective in all disease subtypes associated with genes fusions involving PDGFRA or PDGFRB (which used to be considered as the most severe disease subtypes) [19, 33]. The gene discussed is PDGFRA; the disease is hypereosinophilic syndrome.